Prognostic factors in refractory metastatic colorectal cancer patients treated with Trifluridine/Tipiracil.
Humans
Uracil
/ therapeutic use
Prognosis
Retrospective Studies
Colorectal Neoplasms
/ pathology
Trifluridine
/ therapeutic use
Neoplasm Recurrence, Local
/ drug therapy
Pyrrolidines
/ therapeutic use
Colonic Neoplasms
/ drug therapy
Rectal Neoplasms
/ drug therapy
Drug Combinations
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Chemotherapy
Colorectal cancer
Prognostic factors
Trifluridine/Tipiracil
Journal
Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
received:
29
04
2023
accepted:
20
05
2023
medline:
16
8
2023
pubmed:
15
6
2023
entrez:
15
6
2023
Statut:
ppublish
Résumé
The systemic treatment options for metastatic colorectal cancer (mCRC) are unsatisfactory, and the disease recurs despite the use of numerous medications and their combinations. Trifluridine/Tipiracil is a relatively new drug used in refractory mCRC. Little is known about its real-world effectiveness and prognostic and predictive factors. Therefore, this study aimed to develop a prognostic model for refractory mCRC treated with Trifluridine/Tipiracil. We retrospectively evaluated the data from 163 patients who had received Trifluridine/Tipiracil as a third or fourth line of treatment for refractory mCRC. After starting Trifluridine/Tipiracil, 21.5% of patients survived one year, and the median overall survival after Trifluridine/Tipiracil initiation was 251 days (SD: 17.855; 95%CI: 216-286). Median progression-free survival after Trifluridine/Tipiracil initiation was 56 days (SD: 4.826; 95%CI 47-65). Moreover, the median overall survival from diagnosis was 1333 days (SD: 82.84; 95%CI: 1170-1495). In forward stepwise multivariate Cox regression analysis, initial radical treatment (HR = 0.552, 95% CI 0.372-0.819, p < 0.003), the number of cycles of first-line chemotherapy (HR = 0.978, 95% CI 0.961-0.995, p < 0.011), the number of cycles of second-line chemotherapy (HR = 0.955, 95% CI 0.931-0.98, p < 0.011), BRAF mutation (HR = 3.016, 95% CI = 1.207-7.537, p = 0.018), and hypertension (HR = 0.64, 95% CI = 0.44-0.931, p = 0.02) were all associated with survival after Trifluridine/Tipiracil initiation. Our model and model-based nomogram displayed an AUC of 0.623 for one-year survival estimation in the testing cohort. The C-index for the prediction nomogram was 0.632. We have developed a prognostic model for refractory mCRC treated with Trifluridine/Tipiracil based on five variables. Moreover, we reported a nomogram which could be used by oncologists in clinic visits on a daily basis.
Identifiants
pubmed: 37318592
doi: 10.1007/s00432-023-04909-6
pii: 10.1007/s00432-023-04909-6
pmc: PMC10423107
doi:
Substances chimiques
tipiracil
NGO10K751P
Uracil
56HH86ZVCT
Trifluridine
RMW9V5RW38
Pyrrolidines
0
Drug Combinations
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
10867-10877Informations de copyright
© 2023. The Author(s).
Références
Clin Colorectal Cancer. 2017 Jun;16(2):e15-e22
pubmed: 27670892
Br J Cancer. 2012 Jul 24;107(3):429-34
pubmed: 22735906
Ann Oncol. 2020 Jan;31(1):88-95
pubmed: 31912801
ESMO Open. 2020 Aug;5(4):
pubmed: 32817131
Br J Cancer. 2011 Feb 15;104(4):599-604
pubmed: 21304526
Biochem Pharmacol. 2000 May 15;59(10):1227-36
pubmed: 10736423
Lancet Oncol. 2013 Dec;14(13):1278-86
pubmed: 24225157
Ann Oncol. 2023 Jan;34(1):10-32
pubmed: 36307056
J Clin Oncol. 2008 Mar 10;26(8):1364-70
pubmed: 18323559
Urology. 2003 Dec 29;62 Suppl 1:9-18
pubmed: 14747038
N Engl J Med. 2014 Oct 23;371(17):1609-18
pubmed: 25337750
Lancet Reg Health Eur. 2021 Jan 29;3:100049
pubmed: 34557799
CA Cancer J Clin. 2020 May;70(3):145-164
pubmed: 32133645
N Engl J Med. 2015 May 14;372(20):1909-19
pubmed: 25970050
Ann Oncol. 2009 Feb;20(2):227-30
pubmed: 18842611
J Clin Oncol. 2008 Dec 10;26(35):5705-12
pubmed: 19001320
Lancet Oncol. 2012 Oct;13(10):993-1001
pubmed: 22951287
J Clin Oncol. 2018 Feb 1;36(4):350-358
pubmed: 29215955
N Engl J Med. 2009 Jul 2;361(1):98-9
pubmed: 19571295
Ann Oncol. 2017 Mar 1;28(3):555-561
pubmed: 27864220
Am J Hypertens. 2010 May;23(5):460-8
pubmed: 20186127
Lancet Oncol. 2014 Sep;15(10):1065-75
pubmed: 25088940
Nature. 2012 Jan 26;483(7387):100-3
pubmed: 22281684
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
BMC Cancer. 2016 Jul 13;16:467
pubmed: 27412464
N Engl J Med. 2005 Feb 3;352(5):476-87
pubmed: 15689586
Sci Rep. 2021 Jul 12;11(1):14321
pubmed: 34253805
Int J Clin Oncol. 2020 Apr;25(4):614-621
pubmed: 31838590
Clin Transl Oncol. 2019 Dec;21(12):1781-1785
pubmed: 31209792